Claims
- 1. A method for identifying a candidate for topoisomerase II inhibitor treatment, comprising:
a) providing a candidate subject suspected of having breast cancer cells; b) detecting a copy number for HER-2/neu and topoIIα in said breast cancer cells; and c) identifying said candidate subject as suitable for treatment with a topoisomerase II inhibitor, wherein said identifying comprises demonstrating amplification of said copy number for said HER-2/neu and said topoIIα.
- 2. The method of claim 1, wherein said demonstrating comprises comparing said copy number of said HER-2/neu and said topoIIα to a control copy number.
- 3. The method of claim 2, wherein said copy number of said HER-2/neu is at least 1.5 times greater than said control copy number.
- 4. The method of claim 2, wherein said copy number of said topoIIα is at least 1.5 times greater than said control copy number.
- 5. The method of claim 1, wherein said detecting step further comprises contacting said tissue sample comprising said breast cancer cells with a first probe specific for said HER-2/neu and a second probe specific for said topoIIα.
- 6. The method of claim 5, wherein said second probe comprises at least about 100,000 nucleotides, wherein said second probe hybridizes to a target region of human chromosome seventeen under in situ hybridization conditions, and wherein said target region contains topoIIα gene sequence, but does not contain HER-2/neu gene sequence.
- 7. The method of claim 1, further comprising step d) treating said candidate subject with said topoisomerase II inhibitor.
- 8. The method of claim 1, wherein said detecting step comprises in situ hybridization.
- 9. The method of claim 6, wherein at least one of said probes is detected by chromogenic in situ hybridization.
- 10. A composition comprising a probe, said probe comprising at least about 100,000 nucleotides, wherein said probe hybridizes to a target region of human chromosome seventeen under in-situ hybridization conditions, and wherein said target region contains topoIIα gene sequence, but does not contain HER-2/neu gene sequence.
- 11. The composition of claim 10, wherein said probe comprises no more than 1 million nucleotides.
- 12. The composition of claim 10, wherein said probe contains less than three percent repetitive nucleic acid sequences.
- 13. The composition of claim 10, wherein said probe further comprises a label.
- 14. The composition of claim 10, wherein said target region is at least 500,000 nucleotides from said HER-2/neu gene sequence.
- 15. The composition of claim 10, wherein said target region comprises human chromosome locus 17q11-21.
- 16. A kit comprising;
a) a composition comprising a probe, said probe comprising at least about 100,000 nucleotides, wherein said probe hybridizes to a target region of human chromosome seventeen under in-situ hybridization conditions, and wherein said target region contains topoIIα gene sequence, but does not contain HER-2/neu gene sequence, and b) insert component, wherein said insert component comprises written material.
- 17. The kit of claim 16, wherein said probe further comprises a label.
- 18. The kit of claim 17, further comprising a first antibody specific for said label.
- 19. The kit of claim 18, further comprising a second antibody specific for said first antibody.
- 20. The kit of claim 16, further comprising a second-probe, wherein said second probe specifically detects HER2 or HER2/neu.
Parent Case Info
[0001] The present application claims priority to Provisional Application Serial No. 60/232,660, filed Sep. 14, 2000, hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60232660 |
Sep 2000 |
US |